Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market Snapshot (2023 to 2033)

The global Progressive Fibrosing Interstitial Lung Disease market is currently valued at USD 4742.2 Million in 2023 and is anticipated to expand at a CAGR of 6.2%. Owing to the technological advances in healthcare the market is likely to propel to USD 8654.1 Million by 2033.

The progressive fibrosing interstitial lung disease market is anticipated to increase due to factors such as increased awareness of PF-ILD along with the expected launch of emerging therapies during the forecast period (2023 to 2033).

Report Attribute Details
Expected Market Value (2023) USD 4742.2 Million
Projected Forecast Value (2033) USD 8654.1 Million
Global Growth Rate (2023 to 2033) 6.2% CAGR

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation, and earlier mortality.

Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis.

The type-specific segmentation majorly includes Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and ILDs.
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), are key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of the FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.

PF-ILD treatments that act on the fibrotic pathway are required to slow the progression of fibrosis. Other than IPF, there are few treatment options for advanced fibrotic ILD. Pirfenidone use in PPF patients is associated with a statistically significant reduction in disease progression and protection of lung function.

Exclusive Offer: 30% Off on Regional Reports

Get a free sample report and customize your regions for a 30% discount on your regional report!

Which are Some Prominent Drivers of the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth

Major factors driving the global progressive fibrosing interstitial lung disease treatment market are an increase in the incidence of lung infections, a surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.

Also, the increasing awareness regarding interstitial lung disease treatment among people, availability of cost-effective drugs in the market, and high prevalence of viral infection-causing lung disorder across the globe is expected to be the key factor driving the growth of progressive fibrosing interstitial lung disease treatment market.

The global progressive fibrosing interstitial lung disease treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.

The adoption of Inorganic Strategies by the Market Players is Expected to Drive Market Growth During the Forecast Period.

The increasing number of partnerships by key players is expected to boost the growth of the global interstitial lung disease market during the forecast period. For instance, in September 2020, Boehringer Ingelheim (Canada) Ltd., a pharmaceutical company, announced that they had entered into a partnership with the University Hospital Foundation (UHF), this partnership will focus on improving patient outcomes in the area of progressive fibrosing interstitial lung disease (PF-ILD).

Which are the Trough Areas faced by the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

High Expenditures Associated with Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Research and Development

Although the progressive fibrosing interstitial lung disease treatment market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. The high cost of drugs for the treatment of lung disease will restrain the growth of this market to some extent.

The high expense of therapies has severely hindered their widespread acceptance, particularly in underdeveloped nations. Such high treatment costs are also a subject of worry in developed nations, as many treatments may not be appropriately reimbursed, raising the patient's out-of-pocket expenditures dramatically.

Some side effects after the consumption of anti-inflammatory drugs will also hinder the growth of the progressive fibrosing interstitial lung disease market. All these factors are expected to derail the progress of the progressive fibrosing interstitial lung disease treatment market.

Many drugs have been withdrawn due to clinical challenges in later stages, implying that current emerging drugs may fail and clinical development failure weakens the emerging pipeline. This will disrupt progressive fibrosing interstitial lung disease treatment market growth.

Other factors such as a lack of sensitive clinical outcomes, suitable biomarkers, and difficulty in recruiting subjects, resulting in project delays or cancellations, are hindering the growth of the progressive fibrosing interstitial lung disease treatment market.

Get Brochure on Email

Almost 80% of our clients request uniquely tailored intelligence.

Country-Wise Insights

What Makes USA an Attractive Market for Progressive Fibrosing Interstitial Lung Disease Treatment?

Advancement in Healthcare to Boost the Market Growth in Region

The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 6.0% during the forecast period.

The high prevalence of the disease together with the presence of many leading market players in the region is expected to boost the growth of the North American interstitial lung disease treatment market in the years to come.

The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted for by the US in 2021 (166,393 cases), which are expected to show a rise in the future.

Why Is Europe Emerging as an Opportunistic Progressive Fibrosing Interstitial Lung Disease Treatment Market?

Growing Prevalence of Lung-Related Disorders to Boost the Growth of the Market

Europe is expected to have the second maximum market share of the progressive fibrosing interstitial lung disease treatment market due to the high number of people suffering from COPD and asthma in the region.

Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).

In addition, technologically advanced healthcare facilities are contributing to the growth of the market. Moreover, increasing awareness regarding early therapeutics for lung disease is contributing to the growth of the market. Thus, Europe is expected to possess a 56.7% market share in 2023.

Country-wise Forecast CAGRs for Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market

Countries CAGR
United Kingdom 6.0%
India 5.6%
South Korea 5.7%
China 5.8%
United States of America 6.1%

Category wise Insights

Based on Drug Type, Which Is the Most Prominent Segment in Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

Corticosteroids Segment to Generate Significantly High Revenue

On the basis of drug type progressive fibrosing interstitial lung disease (PFILD) treatment market is classified into Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, and Others. Among these corticosteroids registers the highest demand in the progressive fibrosing interstitial lung disease treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. Corticosteroids, except nintedanib and pirfenidone, are commonly used as first-line therapies for ILDs other than IPF. Except for acute exacerbations, international guidelines for IPF treatment strongly recommend corticosteroid monotherapy.

The corticosteroids segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 5.9% over the forecast period 2022to2023.

By Distribution Channel, which segment generates high revenue in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment market?

Hospital Pharmacy Segment Remains Dominant Among Other Types

The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 65.5%. The growth of the segment is attributed to the increasing prevalence of Progressive Fibrosing Interstitial Lung Disease (PFILD) and hospitalization for treatment.

Hospital pharmacies preserve the stock of products related to Interstitial Lung Disease for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.

The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.

Check Free Sample Report & Save 40%!

Select your niche segments and personalize your insights for smart savings. Cut costs now!

Start-up Scenario

How do New Entrants Contribute to the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market?

With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the progressive fibrosing interstitial lung diseases treatment market.

Some of the start-ups in the progressive fibrosing interstitial lung diseases treatment market include-

  • ILD Insights provides an information app to support the diagnosis and management of lung diseases. The app has features like information and resource materials for healthcare professionals and patient videos featuring opinion leaders, published studies, and clinical practice guidelines.

Competitive Landscape

Some of the key players present in the global progressive fibrosing interstitial lung diseases treatment markets are Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, GNI-EPS Pharmaceuticals, Inc. and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.

  • In February 2022, Boehringer Ingelheim announced that the USA Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis - irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
  • FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, a fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.
  • In March 2020 - Roche announced that the USA Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD
  • In March 2021, F. Hoffmann-La Roche Ltd, a biotech company, announced that the USA Food and Drug Administration (FDA) approved Actemra/RoActemra (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the USA FDA for the treatment of the disease.

Report Scope

Report Attribute Details
Growth Rate CAGR 6.2% from 2023 to 2033
Expected Market Value (2023) USD 4742.2 Million
Projected Forecast Value (2033) USD 8654.1 Million
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Billion & CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis
Segments Covered  Drug Type, Route of Administration, Distribution Channel, Regions
Regions Covered  North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa
Key Countries Profiled  United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel
Key Companies Profiled  Boehringer Ingelheim; Bristol-Myers Squibb; FibroGen; Hoffmann-La Roche Ltd; Pliant Therapeutics, Inc.; United Therapeutics; Vicore Pharma AB; Avalyn Pharmaceuticals; Beijing Continent Pharmaceutical; GNI-EPS Pharmaceuticals, Inc.
Customization Available Upon Request
Table of Content
  • 1. Executive Summary | Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market
  • 2. Market Overview
  • 3. Market Background
  • 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
  • 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
    • 5.1. Corticosteroids
    • 5.2. Immune Suppressing
    • 5.3. Anti-Fibrotic Medication
    • 5.4. Others
  • 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
    • 6.1. Oral
    • 6.2. Injectable
  • 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    • 7.1. Hospital Pharmacies
    • 7.2. Retail Pharmacies
    • 7.3. Online Pharmacies
  • 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    • 8.1. North America
    • 8.2. Latin America
    • 8.3. Europe
    • 8.4. South Asia
    • 8.5. East Asia
    • 8.6. Oceania
    • 8.7. Middle East and Africa (MEA)
  • 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 12. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 13. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 14. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 15. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
  • 16. Key Countries Analysis
  • 17. Market Structure Analysis
  • 18. Competition Analysis
    • 18.1. Boehringer Ingelheim
    • 18.2. Bristol-Myers Squibb
    • 18.3. FibroGen
    • 18.4. Hoffmann-La Roche Ltd
    • 18.5. Pliant Therapeutics, Inc.
    • 18.6. United Therapeutics
    • 18.7. Vicore Pharma AB
    • 18.8. Avalyn Pharmaceuticals
    • 18.9. Beijing Continent Pharmaceutical
    • 18.10. GNI-EPS Pharmaceuticals, Inc.
  • 19. Assumptions & Acronyms Used
  • 20. Research Methodology

Key Segments Covered in the Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market Industry Survey

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Drug Type:

  • Corticosteroids
  • Immune Suppressing
  • Anti-Fibrotic Medication
  • Others

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Route of Administration:

  • Oral
  • Injectable

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Progressive Fibrosing Interstitial Lung Disease (PFILD) Treatment Market by Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What Drives Sales of Anti-biofilm Wound Dressings?

The incidence of diabetic foot ulcers in diabetics and the increasing prevalence of chronic wounds drive market growth.

What is the Growth Forecast for the Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market?

The market is forecast to register a CAGR of 6.2% through 2033.

Who are the Key Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market Players?

Some key players in the global market are Boehringer Ingelheim, Bristol-Myers Squibb, and FibroGen.

How Big will the Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market be by 2033?

The market is estimated to reach USD 8,654.1 million by 2033.

What Limits the Growth Potential of the Market?

High expenditures associated with progressive fibrosing interstitial lung disease (PFILD) treatment research and development limit growth.

Why is the United States Emerging as an Opportunistic Progressive Fibrosing Interstitial Lung Disease Treatment Market?

The high prevalence of the disease, together with the presence of many leading market players in the region, is expected to boost the growth.

Recommendations

Lung Cancer Surgery Market
Estimated Market Size (2024E) USD 1.4 billion
Projected Market Value (2034F) USD 2.5 billion
Value-based CAGR (2024 to 2034) 5.7%
Lung Cancer Therapeutics Market
Estimated Market Size (2024E) USD 37.5 billion
Projected Market Value (2034F) USD 112.8 billion
Value-based CAGR (2024 to 2034) 11.7%
Lung Disease Therapeutics Market
Market Size (2023) USD 83,398.60 million
Market Size (2033) USD 152,369.26 million
Market CAGR (2023 to 2033) 6.2%
Airway Disease Treatment Market
Market Value (2022) USD 1,996.1 Million
Market Anticipated Forecast Value (2032) USD 3,495.3 Million
Market Projected CAGR (2022 to 2032) 5.2%

Explore Therapy Area Insights

View Reports
Trusted By
Future Market Insights

Progressive Fibrosing Interstitial Lung Disease (FLILD) Treatment Market

Schedule a Call